Rock Springs Capital JSPRW Position
Active5-Fund ConvergenceRock Springs Capital held their position in Jasper Therapeutics, Inc. (JSPRW) in Q4 2025, holding $2.0M worth of shares across 1,100,726 shares.
The position was first reported in Q1 2024 and has been tracked across 8 quarterly 13F filings.
JSPRW is a convergence signal: 5 specialist biotech funds hold this stock, suggesting high institutional conviction.
About Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.
Full company profile →Rock Springs Capital JSPRW Position History
Frequently Asked Questions
Does Rock Springs Capital own JSPRW?
Yes. As of Q4 2025, Rock Springs Capital holds 1,100,726 shares of Jasper Therapeutics, Inc. (JSPRW) valued at $2.0M. This data comes from their SEC 13F filing.
How many hedge funds own JSPRW?
5 specialist biotech hedge funds currently hold JSPRW, including BVF Partners, Boxer Capital, Driehaus Capital and 1 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Rock Springs Capital first buy JSPRW?
Rock Springs Capital's position in JSPRW was first reported in Q1 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Rock Springs Capital's JSPRW position increasing or decreasing?
Rock Springs Capital held their JSPRW position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
JSPRWCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Rock Springs CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →